BAS Research, recently granted California’s first medicinal marijuana manufacturing and research license, is teaming with Montel Williams’ LenitivLabs startup to begin developing, producing and marketing medical-grade cannabis products.

BAS’ goal is to replace the social stigma associated with cannabis by creating medical marijuana products with standardized dosing and proven efficacy. Its products are aimed at people with chronic diseases like multiple sclerosis, chronic pain, and serious conditions like cancer or epilepsy.

Dosage inconsistencies are a central problem with medical cannabis in its raw plant form, because potency and purity can vary widely among marijuana strains, and even between batches of the same strain.

Established in 2014, BAS  opened a new facility with a regulated lab and a permit to process cannabis products for research and for the production of marijuana-based medicines in July. It plans to file the regulatory permits necessary for clinical testing of its products throughout 2017, and to begin production early next...